FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2463474703> ?p ?o ?g. }

• W2463474703 endingPage "2017" @default.
• W2463474703 startingPage "2010" @default.
• W2463474703 abstract "BackgroundUp to 15% of patients require coronary artery bypass grafting (CABG) during dual antiplatelet therapy. Available evidence suggests an association between platelet reactivity and CABG-related bleeding. However, platelet reactivity cutoffs for bleeding remain elusive. We sought to explore the association between platelet reactivity and bleeding.MethodsPatients on aspirin and a P2Y12 receptor inhibitor within 48 hours before isolated CABG (n = 149) were enrolled in this prospective study. Blood was drawn 2 to 4 hours preoperatively and platelet reactivity assessed by light transmittance aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP) assay, Multiplate analyzer and Innovance PFA2Y. The primary endpoint was calculated red blood cell loss computed as follows: (blood volume × preoperative hematocrit × 0.91) – (blood volume × hematocrit × 0.91 on postoperative day 5) + (mL of transfused red blood cells × 0.59).ResultsPreoperative platelet reactivity was low [median (interquartile range): LTA: 20 (9–28)%; VASP-PRI: 39 (15–73)%; Multiplate adenosine phosphate test: 16 (12–22) U∗min]. Innovance PFA2Y ≥300 seconds, 72%. Median (IQR) red blood cell loss in patients in first the LTA tertile was 1,449 (1,020 to 1,754) mL compared with 1,107 (858 to 1,512) mL and 1,075 (811 to 1,269) mL in those in the second and third tertiles, respectively (p < 0.004). Bleeding Academic Research Consortium (BARC)-4 bleeding differed between tertiles (62% versus 46% versus 36%; p = 0.037). In a multivariable linear regression model, aspirin dose ≥300 mg, cardiopulmonary bypass time, EuroSCORE, and tertile distribution of platelet reactivity were significantly associated with red blood cell loss.ConclusionsA gradual decrease in red blood cell loss and BARC-4 bleeding occurs with increasing platelet reactivity in patients on antiplatelet therapy undergoing CABG. Our findings support current guidelines to determine time of surgery based on an objective measurement of platelet function (Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery; clinicaltrials.gov NCT01468597). Up to 15% of patients require coronary artery bypass grafting (CABG) during dual antiplatelet therapy. Available evidence suggests an association between platelet reactivity and CABG-related bleeding. However, platelet reactivity cutoffs for bleeding remain elusive. We sought to explore the association between platelet reactivity and bleeding. Patients on aspirin and a P2Y12 receptor inhibitor within 48 hours before isolated CABG (n = 149) were enrolled in this prospective study. Blood was drawn 2 to 4 hours preoperatively and platelet reactivity assessed by light transmittance aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP) assay, Multiplate analyzer and Innovance PFA2Y. The primary endpoint was calculated red blood cell loss computed as follows: (blood volume × preoperative hematocrit × 0.91) – (blood volume × hematocrit × 0.91 on postoperative day 5) + (mL of transfused red blood cells × 0.59). Preoperative platelet reactivity was low [median (interquartile range): LTA: 20 (9–28)%; VASP-PRI: 39 (15–73)%; Multiplate adenosine phosphate test: 16 (12–22) U∗min]. Innovance PFA2Y ≥300 seconds, 72%. Median (IQR) red blood cell loss in patients in first the LTA tertile was 1,449 (1,020 to 1,754) mL compared with 1,107 (858 to 1,512) mL and 1,075 (811 to 1,269) mL in those in the second and third tertiles, respectively (p < 0.004). Bleeding Academic Research Consortium (BARC)-4 bleeding differed between tertiles (62% versus 46% versus 36%; p = 0.037). In a multivariable linear regression model, aspirin dose ≥300 mg, cardiopulmonary bypass time, EuroSCORE, and tertile distribution of platelet reactivity were significantly associated with red blood cell loss. A gradual decrease in red blood cell loss and BARC-4 bleeding occurs with increasing platelet reactivity in patients on antiplatelet therapy undergoing CABG. Our findings support current guidelines to determine time of surgery based on an objective measurement of platelet function (Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery; clinicaltrials.gov NCT01468597)." @default.
• W2463474703 created "2016-07-22" @default.
• W2463474703 creator A5010704137 @default.
• W2463474703 creator A5011626347 @default.
• W2463474703 creator A5012918602 @default.
• W2463474703 creator A5031033759 @default.
• W2463474703 creator A5031535990 @default.
• W2463474703 creator A5044699578 @default.
• W2463474703 creator A5051814197 @default.
• W2463474703 creator A5065717067 @default.
• W2463474703 creator A5083403842 @default.
• W2463474703 creator A5088125363 @default.
• W2463474703 date "2016-12-01" @default.
• W2463474703 modified "2023-10-18" @default.
• W2463474703 title "Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?" @default.
• W2463474703 cites W1835760130 @default.
• W2463474703 cites W1990018236 @default.
• W2463474703 cites W1998869090 @default.
• W2463474703 cites W2008000663 @default.
• W2463474703 cites W2009355503 @default.
• W2463474703 cites W2028161433 @default.
• W2463474703 cites W2031032188 @default.
• W2463474703 cites W2049036705 @default.
• W2463474703 cites W2053288424 @default.
• W2463474703 cites W2068635657 @default.
• W2463474703 cites W2072518791 @default.
• W2463474703 cites W2097690722 @default.
• W2463474703 cites W2111126857 @default.
• W2463474703 cites W2114879453 @default.
• W2463474703 cites W2117976231 @default.
• W2463474703 cites W2122779695 @default.
• W2463474703 cites W2140501627 @default.
• W2463474703 cites W2147186417 @default.
• W2463474703 cites W2156202966 @default.
• W2463474703 cites W2156255513 @default.
• W2463474703 cites W2161055506 @default.
• W2463474703 cites W2169387542 @default.
• W2463474703 cites W4236531408 @default.
• W2463474703 cites W79691165 @default.
• W2463474703 doi "https://doi.org/10.1016/j.athoracsur.2016.05.003" @default.
• W2463474703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27378554" @default.
• W2463474703 hasPublicationYear "2016" @default.
• W2463474703 type Work @default.
• W2463474703 sameAs 2463474703 @default.
• W2463474703 citedByCount "34" @default.
• W2463474703 countsByYear W24634747032016 @default.
• W2463474703 countsByYear W24634747032017 @default.
• W2463474703 countsByYear W24634747032018 @default.
• W2463474703 countsByYear W24634747032019 @default.
• W2463474703 countsByYear W24634747032020 @default.
• W2463474703 countsByYear W24634747032021 @default.
• W2463474703 countsByYear W24634747032022 @default.
• W2463474703 countsByYear W24634747032023 @default.
• W2463474703 crossrefType "journal-article" @default.
• W2463474703 hasAuthorship W2463474703A5010704137 @default.
• W2463474703 hasAuthorship W2463474703A5011626347 @default.
• W2463474703 hasAuthorship W2463474703A5012918602 @default.
• W2463474703 hasAuthorship W2463474703A5031033759 @default.
• W2463474703 hasAuthorship W2463474703A5031535990 @default.
• W2463474703 hasAuthorship W2463474703A5044699578 @default.
• W2463474703 hasAuthorship W2463474703A5051814197 @default.
• W2463474703 hasAuthorship W2463474703A5065717067 @default.
• W2463474703 hasAuthorship W2463474703A5083403842 @default.
• W2463474703 hasAuthorship W2463474703A5088125363 @default.
• W2463474703 hasBestOaLocation W24634747031 @default.
• W2463474703 hasConcept C119060515 @default.
• W2463474703 hasConcept C126322002 @default.
• W2463474703 hasConcept C164705383 @default.
• W2463474703 hasConcept C2776820930 @default.
• W2463474703 hasConcept C2777628954 @default.
• W2463474703 hasConcept C2777849778 @default.
• W2463474703 hasConcept C2780959883 @default.
• W2463474703 hasConcept C42219234 @default.
• W2463474703 hasConcept C49059817 @default.
• W2463474703 hasConcept C71924100 @default.
• W2463474703 hasConcept C78529466 @default.
• W2463474703 hasConcept C89560881 @default.
• W2463474703 hasConceptScore W2463474703C119060515 @default.
• W2463474703 hasConceptScore W2463474703C126322002 @default.
• W2463474703 hasConceptScore W2463474703C164705383 @default.
• W2463474703 hasConceptScore W2463474703C2776820930 @default.
• W2463474703 hasConceptScore W2463474703C2777628954 @default.
• W2463474703 hasConceptScore W2463474703C2777849778 @default.
• W2463474703 hasConceptScore W2463474703C2780959883 @default.
• W2463474703 hasConceptScore W2463474703C42219234 @default.
• W2463474703 hasConceptScore W2463474703C49059817 @default.
• W2463474703 hasConceptScore W2463474703C71924100 @default.
• W2463474703 hasConceptScore W2463474703C78529466 @default.
• W2463474703 hasConceptScore W2463474703C89560881 @default.
• W2463474703 hasIssue "6" @default.
• W2463474703 hasLocation W24634747031 @default.
• W2463474703 hasLocation W24634747032 @default.
• W2463474703 hasOpenAccess W2463474703 @default.
• W2463474703 hasPrimaryLocation W24634747031 @default.
• W2463474703 hasRelatedWork W1877581810 @default.
• W2463474703 hasRelatedWork W2010454652 @default.
• W2463474703 hasRelatedWork W2013641304 @default.
• W2463474703 hasRelatedWork W2076238851 @default.

• next